Last reviewed · How we verify

Zoledronic acid IV

National Taiwan University Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Zoledronic acid IV is a Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved.

Zoledronic acid IV is a small molecule inhibitor of farnesyl diphosphate synthase, a class of drugs known as INHIBITORS. It has been studied for various conditions, including Multiple Myeloma, Breast Cancer, Metastatic Bone Disease, Postmenopausal Osteoporosis, and Postmenopausal Osteopenia.

At a glance

Generic nameZoledronic acid IV
SponsorNational Taiwan University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Zoledronic acid IV

What is Zoledronic acid IV?

Zoledronic acid IV is a Small molecule drug developed by National Taiwan University Hospital.

Who makes Zoledronic acid IV?

Zoledronic acid IV is developed and marketed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

What development phase is Zoledronic acid IV in?

Zoledronic acid IV is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing